Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to read this report
- Benchmark Mitsubishi Tanabe' s performance against key rivals in the ethical pharmaceutical sector
- See how the merger of Mitsubishi and Tanabe has significantly altered the company' s strategic priorities and resource capabilities
View Cart
